Evidence for the efficacy and safety of anti-interleukin-5 treatment in the management of refractory eosinophilic asthma

Therapeutic Advances in Respiratory Disease

Volumn 9, Issue 4, 2015, Pages 135-145

  Hilvering, Bart ^a,b   Xue, Luzheng ^a   Pavord, Ian D ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

asthma; benralizumab; eosinophilia; IL 5; IL 5 blocker; mepolizumab; refractory asthma; reslizumab; severe asthma

Indexed keywords

ANTIASTHMATIC AGENT; BENRALIZUMAB; IL5 PROTEIN, HUMAN; INTERLEUKIN 5; MEPOLIZUMAB; MONOCLONAL ANTIBODY; RESLIZUMAB; CORTICOSTEROID; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR; INTERLEUKIN 13; INTERLEUKIN 25; INTERLEUKIN 33; INTERLEUKIN 5 RECEPTOR; JANUS KINASE 2; PLACEBO; PROTEIN KINASE LYN;

ANIMAL; ANTAGONISTS AND INHIBITORS; ASTHMA; EOSINOPHIL; EOSINOPHILIA; HUMAN; IMMUNOLOGY; METABOLISM; PATHOPHYSIOLOGY; SEVERITY OF ILLNESS INDEX; B LYMPHOCYTE ACTIVATION; CHEMOTAXIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CYTOKINE PRODUCTION; DISEASE EXACERBATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; EOSINOPHIL COUNT; FORCED EXPIRATORY VOLUME; LUNG FUNCTION; NATURAL KILLER CELL; ORAL BIOPSY; PEAK EXPIRATORY FLOW; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REFRACTORY EOSINOPHILIC ASTHMA; REVIEW; RHINOPHARYNGITIS; SINGLE DRUG DOSE; TREATMENT RESPONSE;

ANIMALS; ANTI-ASTHMATIC AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; ASTHMA; EOSINOPHILIA; EOSINOPHILS; HUMANS; INTERLEUKIN-5; SEVERITY OF ILLNESS INDEX;

EID: 84937039082     PISSN: 17534658     EISSN: 17534666     Source Type: Journal    
DOI: 10.1177/1753465815581279     Document Type: Review

References (32)

1. Bafadhel M. McKenna S. Terry S. Mistry V. Pancholi M. Venge P. (2012) Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial. Am J Respir Crit Care Med 186: 48–55.
2. Bafadhel M. McKenna S. Terry S. Mistry V. Reid C. Haldar P. (2011) Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med 184: 662–671.
3. Bel E. Wenzel S. Thompson P. Prazma C. Keene O. Yancey S. (2014) Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med 371: 1189–1197.
4. Brightling C. Bleecker E. Panettieri R. Bafadhel M. She D. Ward C. (2014) Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study. Lancet Respir Med 2: 891–901.
5. Castro M. Wenzel S. Bleecker E. Pizzichini E. Kuna P. Busse W. (2014) Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. Lancet Respir Med 2: 879–890.
6. Chlumsky J. Striz I. Terl M. Vondracek J. (2006) Strategy aimed at reduction of sputum eosinophils decreases exacerbation rate in patients with asthma. J Int Med Res 34: 129-139.
7. Chung K. Wenzel S. Brozek J. Bush A. Castro M. Sterk P. (2014) International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 43: 343–373.
8. Egan R. Athwal D. Bodmer M. Carter J. Chapman R. Chou C. (1999) Effect of Sch 55700, a humanized monoclonal antibody to human interleukin-5, on eosinophilic responses and bronchial hyperreactivity. Arzneimittelforschung 49: 779–790.
9. Flood-Page P. Menzies-Gow A. Kay A. Robinson D. (2003a) Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med 167: 199–204.
10. Flood-Page P. Menzies-Gow A. Phipps S. Ying S. Wangoo A. Ludwig M. (2003b) Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J Clin Invest 112: 1029-1036.
11. Flood-Page P. Swenson C. Faiferman I. Matthews J. Williams M. Brannick L. (2007) A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med 176: 1062–1071.
12. Green R. Brightling C. McKenna S. Hargadon B. Parker D. Bradding P. (2002) Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 360: 1715–1721.
13. Haldar P. Brightling C. Hargadon B. Gupta S. Monteiro W. Sousa A. (2009) Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 360: 973–984.
14. Hanania N. Wenzel S. Rosén K. Hsieh H. Mosesova S. Choy D. (2013) Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med 187: 804–811.
15. Jayaram L. Pizzichini M. Cook R. Boulet L. Lemière C. Pizzichini E. (2006) Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations. Eur Respir J 27: 483–494.
16. Kips J. O–Connor B. Langley S. Woodcock A. Kerstjens H. Postma D. (2003) Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study. Am J Respir Crit Care Med 167: 1655–1659.
17. Klein Wolterink R. Kleinjan A. van Nimwegen M. Bergen I. de Bruijn M. Levani Y. (2012) Pulmonary innate lymphoid cells are major producers of IL-5 and IL-13 in murine models of allergic asthma. Eur J Immunol 42: 1106–1116.
18. Laviolette M. Gossage D. Gauvreau G. Leigh R. Olivenstein R. Katial R. (2013) Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. J Allergy Clin Immunol 132: 1086–1096.e5.
19. Leckie M. ten Brinke A. Khan J. Diamant Z. O–Connor B. Walls C. 2000. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 356: 2144–2148.
20. Linch S. Danielson E. Kelly A. Tamakawa R. Lee J. Gold J. (2012) Interleukin 5 is protective during sepsis in an eosinophil-independent manner. Am J Respir Crit Care Med 186: 246–254.
21. Loymans R. Gemperli A. Cohen J. Rubinstein S. Sterk P. Reddel H. (2014) Comparative effectiveness of long term drug treatment strategies to prevent asthma exacerbations: network meta-analysis. BMJ 348: g3009.
22. Milburn M. Hassell A. Lambert M. Jordan S. Proudfoot A. Graber P. (1993) A novel dimer configuration revealed by the crystal structure at 2.4 A resolution of human interleukin-5. Nature 363: 172–176.
23. N Engl J Med., (November, 1997) Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. 13; 337(20): 1405–11.
24. Nair P. Pizzichini M. Kjarsgaard M. Inman M. Efthimiadis A. Pizzichini E. (2009) Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 360: 985–993.
25. Ortega H. Liu M. Pavord I. Brusselle G. FitzGerald J. Chetta A. (2014) Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 371: 1198–1207.
26. Pavord I. (2013) Complex airway disease: an approach to assessment and management. Lancet Respir Med 1: 84–90.
27. Pavord I. Korn S. Howarth P. Bleecker E. Buhl R. Keene O. (2012) Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 380: 651-659.
28. Shi H. Qin S. Huang G. Chen Y. Xiao C. Xu H. (1997) Infiltration of eosinophils into the asthmatic airways caused by interleukin 5. Am J Respir Cell Mol Biol 16: 220–224.
29. Stirling R. van Rensen E. Barnes P. Chung K. (2001) Interleukin-5 induces CD34(+) eosinophil progenitor mobilization and eosinophil CCR3 expression in asthma. Am J Respir Crit Care Med 164: 1403–1409.
30. Takatsu K. (2013) Interleukin-5 and its receptor molecules. In: Lee J. Rosenberg H. (eds) Eosinophils in Health and Disease. New York: Academic Press, pp. 97–103.
31. Van Rensen E. Stirling R. Scheerens J. Staples K. Sterk P. Barnes P. (2001) Evidence for systemic rather than pulmonary effects of interleukin-5 administration in asthma. Thorax 56: 935–940.
32. World Health Organization (2007) Global surveillance, prevention and control of chronic respiratory diseases: a comprehensive approach.